Inclusion Criteria - Cell Procurement:

          -  Written informed consent for procurement signed by subject or legal guardian of a
             pediatric subject and HIPAA authorization for release of personal health information.

          -  Age 3 to 17 years of age for pediatric subjects (weight must be ≥ 10 kg), ≥ 18 to 70
             years of age for adults at the time of consent.

          -  Karnofsky score > 60% if > 16 years old or Lansky performance score of greater than
             60% if <16 years old.

          -  Relapsed or refractory precursor B cell ALL:

          -  Second or greater bone marrow relapse OR

          -  Any bone marrow relapse >100 days after allogeneic stem cell transplant OR

          -  Primary refractory ALL defined as no complete response after 2 cycles of a standard of
             care chemotherapy regimen OR

          -  For adult subjects: first bone marrow relapse with duration of first CR <1 year OR
             first CR duration >/=1 year and refractory to >/= 1 cycle of therapy for treatment of
             relapse.

          -  Subjects with isolated non-CNS extramedullary disease will be eligible as long as the
             time-of-remission criteria above for bone marrow relapses or primary refractory ALL
             are met and the biopsy for extramedullary disease confirms CD19 expression

          -  For pediatric subjects: first bone marrow or isolated non-CNS extramedullary relapse
             refractory to 1 cycle of standard therapy for relapsed ALL.

          -  While active CNS3 leukemia will be excluded, subjects with concurrent CNS3 disease and
             bone marrow relapse who have responded to CNS-directed therapy prior to enrollment
             will be allowed to participate. Intrathecal chemotherapy will be allowed to continue
             between lymphodepleting chemotherapy and cell infusion.

          -  Subjects with CNS2 disease and concurrent bone marrow relapse will be eligible.
             Intrathecal chemotherapy will be allowed to continue between lymphodepleting
             chemotherapy and cell infusion.

          -  Subjects with Ph+ ALL will be eligible if they have failed ≥ 2 ABL tyrosine kinase
             inhibitors. Subjects with the T315I ABL kinase point mutation will be eligible if they
             have failed ponatinib-containing therapy, regardless of the number of prior ABL
             tyrosine kinase inhibitors.

          -  CD19 positivity of lymphoblasts confirmed by flow cytometry or immunohistochemistry
             per institutional standards.

          -  Life expectancy ≥ 12 weeks.

          -  Demonstrate adequate renal and hepatic function as defined in the table below; all
             screening labs to be obtained within 72 hrs prior to procurement.

               -  Serum Creatinine: ≤ 1.5 x ULN

               -  Bilirubin: ≤ 1.5 x upper limit of normal (ULN), unless attributed to Gilbert's
                  Syndrome

               -  Aspartate Aminotransferase (AST): ≤ 3.0 × ULN

               -  Alanine aminotransferase (ALT): ≤ 3.0 × ULN

               -  For pediatric patients, adequate renal function is defined below:

        Age Maximum Serum Creatinine (mg/dL) Male Female 3 to <6 years ≤0.8 ≤0.8 6 to <10 years ≤1
        ≤1 10 to <13 years ≤1.2 ≤1.2 13 to <16 years ≤1.5 ≤1.4 16 to <18 years ≤1.7 ≤1.4

          -  Females of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to procurement.

          -  Females and males of childbearing potential must be willing to abstain from
             heterosexual activity or to use 2 forms of effective methods of contraception from the
             time of informed consent until 3 months after treatment discontinuation. The two
             contraception methods can be comprised of two barrier methods, or a barrier method
             plus a hormonal method. Female participants will inform their male partners that they
             must use the methods of birth control required by the protocol.

          -  Male subjects with female partners must have had a prior vasectomy or agree to use an
             adequate method of contraception (i.e., double barrier method: condom plus spermicidal
             agent) starting with the first dose of study therapy through 3 months after the last
             dose of study therapy.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures.

          -  Subjects currently receiving "maintenance" doses of chemotherapy are eligible and the
             need for intrathecal prophylaxis prior to procurement is left to the discretion of the
             investigator. Maintenance doses of chemotherapy are defined as methotrexate ≤30
             mg/m2/week, mercaptopurine ≤100 mg/m2/day and vincristine ≤ 2 mg/28 days.
             Corticosteroid-containing maintenance therapy is permitted only if corticosteroids are
             administered >14 days prior to procurement.

        Exclusion Criteria - Cell Procurement:

          -  Subjects with relapsed fulminant CD19+ ALL that is rapidly progressing who cannot
             safely delay definitive treatment for their ALL by at least 4 weeks in the opinion of
             the investigator.

          -  Lumbar puncture must be performed prior to procurement and subjects with evidence of
             CNS3 disease will be excluded from study entry. Subjects with concurrent CNS3 disease
             and bone marrow relapse who have responded to CNS-directed therapy prior to
             enrollment/lymphodepletion will be allowed to participate. Subjects with CNS2 disease
             and concurrent bone marrow relapse will be eligible. Intrathecal chemotherapy will be
             allowed to continue between lymphodepleting chemotherapy and cell infusion.

          -  Pregnant or breastfeeding.

          -  Has a known additional malignancy that is active and/or progressive requiring
             treatment; exceptions include basal cell or squamous cell skin cancer, in situ
             cervical or bladder cancer, or other cancer for which the subject has been
             disease-free for at least five years.

          -  Subjects must not have tumor in a location where enlargement could cause airway
             obstruction.

          -  Subjects may not have an oxygen requirement as defined by pulse oximetry of < 90% on
             room air.

          -  Subjects must not have left ventricular ejection fraction of <40% (shortening fraction
             <27% for pediatric subjects) as measured by echocardiogram or MUGA.

          -  Patients with the following systemic viral infections will be excluded: active HIV,
             HTLV, HBV, HCV (tests can be pending at the time of cell procurement; only those
             samples confirming lack of active infection will be used to generate transduced cells)
             Note: To meet eligibility subjects are required to be negative for HIV antibody or HIV
             viral load, negative for HTLV1 and 2 antibody or PCR negative for HTLV1 and 2,
             negative for Hepatitis B surface antigen, or negative for HCV antibody or HCV viral
             load.

          -  Patients who are on treatment for other active uncontrolled infections (not referenced
             above) with resolution of signs/symptoms are not excluded. Non-influenza, non-RSV,
             isolated upper respiratory infections are not excluded. Other active uncontrolled
             infections will be excluded.

          -  Prior to procurement current use of systemic corticosteroids at doses ≥10mg/day
             prednisone or its equivalent; those receiving <10mg/day may be enrolled at discretion
             of investigator. Physiologic replacement with hydrocortisone is allowed at doses 6-12
             mg/m2/day, or equivalent.

          -  Received anti-CD19 antibody-based therapy OR cytotoxic chemotherapy not described as
             maintenance therapy in the procurement inclusion criteria within 2 weeks of
             procurement.

        Inclusion Criteria - Lymphodepletion

          -  Written informed consent for the main study signed by subject or legal guardian of a
             pediatric subject.

          -  Karnofsky score > 60% if ≥16 years old or Lansky performance score of greater than 60%
             if <16 years old

          -  Life expectancy ≥ 12 weeks.

          -  Subjects who have received prior therapy with murine antibodies must have
             documentation of absence of human anti-mouse antibodies (HAMA) prior to
             lymphodepletion on this study.

          -  Demonstrate adequate renal and hepatic function as defined in the table below; all
             screening labs to be obtained within 72 hrs prior to lymphodepletion.

               -  Serum Creatinine: ≤ 1.5 x ULN

               -  Bilirubin: ≤ 1.5 x upper limit of normal (ULN), unless attributed to Gilbert's
                  Syndrome

               -  Aspartate Aminotransferase (AST): ≤ 3.0 × ULN

               -  Alanine aminotransferase (ALT): ≤ 3.0 × ULN

               -  For pediatric patients, adequate renal function is defined below:

        Age Maximum Serum Creatinine (mg/dL) Male Female 3 to <6 years ≤0.8 ≤0.8 6 to <10 years ≤1
        ≤1 10 to <13 years ≤1.2 ≤1.2 13 to <16 years ≤1.5 ≤1.4 16 to <18 years ≤1.7 ≤1.4

          -  Females of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to 72 hours prior to lymphodepletion.

          -  Females and males of childbearing potential must be willing to abstain from
             heterosexual activity or to use 2 forms of effective methods of contraception from the
             time of informed consent until 3 months after treatment discontinuation. The two
             contraception methods can be comprised of two barrier methods, or a barrier method
             plus a hormonal method. Female participants will inform their male partners that they
             must use the methods of birth control required by the protocol.

          -  Male subjects with female partners must have had a prior vasectomy or agree to use an
             adequate method of contraception (i.e., double barrier method: condom plus spermicidal
             agent) starting with the first dose of study therapy through 3 months after the last
             dose of study therapy.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures.

          -  Subjects currently receiving "maintenance" doses of chemotherapy are eligible and the
             need for intrathecal prophylaxis prior to lymphodepletion is left to the discretion of
             the investigator. Maintenance chemotherapy is defined as methotrexate ≤30 mg/m2/week,
             mercaptopurine ≤100 mg/m2/day and vincristine ≤ 2 mg/28 days. For subjects who receive
             chemotherapy, including intrathecal chemotherapy, that does not fit this definition of
             maintenance chemotherapy, a two week washout between the last dose of standard of care
             chemotherapy and the beginning of lymphodepletion will be required.

          -  Subjects must have autologous transduced activated T-cells that meet the Certificate
             of Analysis (CofA) acceptance criteria.

        Exclusion Criteria- Lymphodepletion

          -  Pregnant or breastfeeding.

          -  Has a known additional malignancy that is active and/or progressive requiring
             treatment; exceptions include basal cell or squamous cell skin cancer, in situ
             cervical or bladder cancer, or other cancer for which the subject has been
             disease-free for at least five years.

          -  Subjects must not have tumor in a location where enlargement could cause airway
             obstruction.

          -  Subjects may not have an oxygen requirement as defined by pulse oximetry of < 90% on
             room air.

          -  Treatment with any investigational drug within 14 days (ie, two weeks) prior to
             lymphodepletionn or has received any tumor vaccines within the previous five weeks
             prior to lymphodepletion.

          -  Patients with the following systemic viral infections will be excluded: active HIV,
             HTLV, HBV, HCV. Note: To meet eligibility subjects are required to be negative for HIV
             antibody or HIV viral load, negative for HTLV1 and 2 antibody or PCR negative for
             HTLV1 and 2, negative for Hepatitis B surface antigen, or negative for HCV antibody or
             HCV viral load.

          -  Patients who are on treatment for other active uncontrolled infections (not referenced
             above) with resolution of signs/symptoms are not excluded. Non-influenza, non-RSV,
             isolated upper respiratory infections are not excluded. Other active uncontrolled
             infections will be excluded.

          -  Use of systemic corticosteroids at doses ≥10mg/day prednisone or its equivalent; those
             receiving <10mg/day may be enrolled at discretion of investigator. Physiologic
             replacement with hydrocortisone is allowed at 6-12 mg/m2/day, or equivalent.

        Inclusion Criteria- iC9-CAR19 Cell Infusion

          -  Females and males of childbearing potential must be willing to abstain from
             heterosexual activity or to use 2 forms of effective methods of contraception from the
             time of informed consent until 3 months after treatment discontinuation. The two
             contraception methods can be comprised of two barrier methods, or a barrier method
             plus a hormonal method. Female participants will inform their male partners that they
             must use the methods of birth control required by the protocol.

          -  Male subjects with female partners must have had a prior vasectomy or agree to use an
             adequate method of contraception (i.e., double barrier method: condom plus spermicidal
             agent) starting with the first dose of study therapy through 3 months after the last
             dose of study therapy.

          -  As determined by the enrolling physician or protocol designee, ability of the subject
             to understand and comply with study procedures.

        Exclusion Criteria- iC9-CAR19 Cell Infusion

          -  Corticosteroid use is contraindicated following iC9-CAR19 infusion unless medically
             necessary e.g., to treat CRS).

          -  Severe systemic uncontrolled disease or toxicities that develop after lymphodepletion
             may prompt exclusion from cell infusion at the discretion of the investigator.